{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:47:47Z","timestamp":1792468067199,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67254-x","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:18:45Z","timestamp":1765837125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["\u03b1PD-1-conjugated acid-cleavable nanodrugs overcomes cellular immunotherapy barriers in pancreatic tumors"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-8307","authenticated-orcid":false,"given":"Ziqi","family":"Gan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4271-0310","authenticated-orcid":false,"given":"Xintao","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7923-5309","authenticated-orcid":false,"given":"Zecong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"67254_CR1","first-page":"166","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard, A. FDA approves fourth CAR-T cell therapy. Nat. Rev. Drug Discov. 20, 166 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"67254_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai, K. et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J. Hematol. Oncol. 17, 105 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"67254_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"67254_CR4","doi-asserted-by":"publisher","first-page":"1018962","DOI":"10.3389\/fimmu.2022.1018962","volume":"13","author":"MH Kazemi","year":"2022","unstructured":"Kazemi, M. H. et al. Tumor-infiltrating lymphocytes for treatment of solid tumors: it takes two to tango? Front. Immunol. 13, 1018962 (2022).","journal-title":"Front. Immunol."},{"key":"67254_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02006-4","volume":"19","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med. 19, 140 (2021).","journal-title":"BMC Med."},{"key":"67254_CR6","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.3390\/cancers14174160","volume":"14","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers 14, 4160 (2022).","journal-title":"Cancers"},{"key":"67254_CR7","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-18-0900","volume":"27","author":"R Hester","year":"2021","unstructured":"Hester, R., Mazur, P. K. & McAllister, F. Immunotherapy in pancreatic adenocarcinoma: beyond \u201ccopy\/paste\u201d. Clin. Cancer Res. 27, 6287\u20136297 (2021).","journal-title":"Clin. Cancer Res."},{"key":"67254_CR8","doi-asserted-by":"publisher","first-page":"1258538","DOI":"10.3389\/fimmu.2023.1258538","volume":"14","author":"J Guo","year":"2023","unstructured":"Guo, J., Wang, S. & Gao, Q. An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer. Front. Immunol. 14, 1258538 (2023).","journal-title":"Front. Immunol."},{"key":"67254_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-023-02935-3","volume":"43","author":"W Luo","year":"2024","unstructured":"Luo, W., Wen, T. & Qu, X. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept. J. Exp. Clin. Cancer Res. 43, 8 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"67254_CR10","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","volume":"38","author":"AS Bear","year":"2020","unstructured":"Bear, A. S., Vonderheide, R. H. & O\u2019Hara, M. H. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell 38, 788\u2013802 (2020).","journal-title":"Cancer Cell"},{"key":"67254_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay7785","volume":"6","author":"Z Xiao","year":"2020","unstructured":"Xiao, Z. et al. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-kappaB inhibitor for antitumor immunotherapy. Sci. Adv. 6, eaay7785 (2020).","journal-title":"Sci. Adv."},{"key":"67254_CR12","doi-asserted-by":"publisher","first-page":"102102","DOI":"10.1016\/j.nantod.2023.102102","volume":"54","author":"J Huang","year":"2024","unstructured":"Huang, J., Xiao, Z., Lin, M., Zhong, H. & Shuai, X. Metal-organic framework nanoparticles hitchhiking on T cells for protein delivery to boost anticancer immunotherapy. Nano Today 54, 102102 (2024).","journal-title":"Nano Today"},{"key":"67254_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nbt.4181","volume":"36","author":"L Tang","year":"2018","unstructured":"Tang, L. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. 36, 707\u2013716 (2018).","journal-title":"Nat. Biotechnol."},{"key":"67254_CR14","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.1016\/j.biomaterials.2012.04.029","volume":"33","author":"MT Stephan","year":"2012","unstructured":"Stephan, M. T., Stephan, S. B., Bak, P., Chen, J. & Irvine, D. J. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials 33, 5776\u20135787 (2012).","journal-title":"Biomaterials"},{"key":"67254_CR15","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/anie.201813060","volume":"58","author":"G Chen","year":"2019","unstructured":"Chen, G. et al. A convenient and versatile amino-acid-boosted biomimetic strategy for the nondestructive encapsulation of biomacromolecules within metal-organic frameworks. Angew. Chem. Int. Ed. 58, 1463\u20131467 (2019).","journal-title":"Angew. Chem. Int. Ed."},{"key":"67254_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41565-023-01378-3","volume":"18","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Non-invasive activation of intratumoural gene editing for improved adoptive T-cell therapy in solid tumours. Nat. Nanotechnol. 18, 933\u2013944 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"67254_CR17","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","volume":"35","author":"D Dangaj","year":"2019","unstructured":"Dangaj, D. et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell 35, 885\u2013900 (2019).","journal-title":"Cancer Cell"},{"key":"67254_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2022.101490","volume":"44","author":"Z Xiao","year":"2022","unstructured":"Xiao, Z. et al. Nanodrug simultaneously regulates stromal extracellular matrix and glucose metabolism for effective immunotherapy against orthotopic pancreatic cancer. Nano Today 44, 101490 (2022).","journal-title":"Nano Today"},{"key":"67254_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jconrel.2023.02.029","volume":"356","author":"Z Xiao","year":"2023","unstructured":"Xiao, Z. et al. Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy. J. Control. Release 356, 360\u2013372 (2023).","journal-title":"J. Control. Release"},{"key":"67254_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2021","unstructured":"Paijens, S. T., Vledder, A., de Bruyn, M. & Nijman, H. W. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell. Mol. Immunol. 18, 842\u2013859 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"67254_CR21","doi-asserted-by":"publisher","first-page":"594540","DOI":"10.3389\/fimmu.2020.594540","volume":"11","author":"ZC Ding","year":"2020","unstructured":"Ding, Z. C., Aboelella, N. S., Bryan, L., Shi, H. & Zhou, G. The monocytes that repopulate in mice after cyclophosphamide treatment acquire a neutrophil precursor gene signature and immunosuppressive activity. Front. Immunol. 11, 594540 (2020).","journal-title":"Front. Immunol."},{"key":"67254_CR22","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","volume":"6","author":"A Emadi","year":"2009","unstructured":"Emadi, A., Jones, R. J. & Brodsky, R. A. Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol. 6, 638\u2013647 (2009).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"67254_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu, Z. I. & O\u2019Reilly, E. M. Therapeutic developments in pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 21, 7\u201324 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"67254_CR24","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao, L. & Cao, Y. J. Engineered T cell therapy for cancer in the clinic. Front. Immunol. 10, 2250 (2019).","journal-title":"Front. Immunol."},{"key":"67254_CR25","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1158\/0008-5472.CAN-17-0236","volume":"77","author":"SM Fernandez-Poma","year":"2017","unstructured":"Fernandez-Poma, S. M. et al. Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy. Cancer Res. 77, 3672\u20133684 (2017).","journal-title":"Cancer Res."},{"key":"67254_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/d41573-024-00035-1","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers. Nat. Rev. Drug Discov. 23, 238 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"67254_CR27","doi-asserted-by":"publisher","first-page":"e003887","DOI":"10.1136\/jitc-2021-003887","volume":"10","author":"J Guo","year":"2022","unstructured":"Guo, J. et al. Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen. J. Immunother. Cancer 10, e003887 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"67254_CR28","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan, B. C. et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat. Med. 27, 1410\u20131418 (2021).","journal-title":"Nat. Med."},{"key":"67254_CR29","doi-asserted-by":"publisher","unstructured":"Reardon, S. First cell therapy for solid tumours heads to the clinic: what it means for cancer treatment. https:\/\/doi.org\/10.1038\/d41586-024-00673-w (2024).","DOI":"10.1038\/d41586-024-00673-w"},{"key":"67254_CR30","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41551-021-00737-6","volume":"5","author":"S Lesch","year":"2021","unstructured":"Lesch, S. et al. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat. Biomed. Eng. 5, 1246\u20131260 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"67254_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101\u2013124 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"67254_CR32","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","volume":"19","author":"MS Goldberg","year":"2019","unstructured":"Goldberg, M. S. Improving cancer immunotherapy through nanotechnology. Nat. Rev. Cancer 19, 587\u2013602 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"67254_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2017.05.011","volume":"114","author":"L Milling","year":"2017","unstructured":"Milling, L., Zhang, Y. & Irvine, D. J. Delivering safer immunotherapies for cancer. Adv. Drug Deliv. Rev. 114, 79\u2013101 (2017).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"67254_CR34","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1002\/ijc.23756","volume":"123","author":"CM van Herpen","year":"2008","unstructured":"van Herpen, C. M. et al. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int. J. Cancer 123, 2354\u20132361 (2008).","journal-title":"Int. J. Cancer"},{"key":"67254_CR35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0277-5379(89)90034-5","volume":"25","author":"MG Pfreundschuh","year":"1989","unstructured":"Pfreundschuh, M. G. et al. Phase I study of intratumoral application of recombinant human tumor necrosis factor. Eur. J. Cancer Clin. Oncol. 25, 379\u2013388 (1989).","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"67254_CR36","doi-asserted-by":"publisher","first-page":"291ra294","DOI":"10.1126\/scitranslmed.aaa5447","volume":"7","author":"B Huang","year":"2015","unstructured":"Huang, B. et al. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci. Transl. Med. 7, 291ra294 (2015).","journal-title":"Sci. Transl. Med."},{"key":"67254_CR37","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 22, 659\u2013661 (2008).","journal-title":"FASEB J."},{"key":"67254_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"67254_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00281-018-0703-z","volume":"41","author":"O Met","year":"2019","unstructured":"Met, O., Jensen, K. M., Chamberlain, C. A., Donia, M. & Svane, I. M. Principles of adoptive T cell therapy in cancer. Semin. Immunopathol. 41, 49\u201358 (2019).","journal-title":"Semin. Immunopathol."},{"key":"67254_CR40","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","volume":"28","author":"ST Levi","year":"2022","unstructured":"Levi, S. T. et al. Neoantigen identification and response to adoptive cell transfer in anti-PD-1 naive and experienced patients with metastatic melanoma. Clin. Cancer Res. 28, 3042\u20133052 (2022).","journal-title":"Clin. Cancer Res."},{"key":"67254_CR41","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1158\/1078-0432.CCR-22-0832","volume":"28","author":"E Blass","year":"2022","unstructured":"Blass, E. & Ott, P. A. PD-1 inhibition-trouble for subsequent TIL therapy in patients with melanoma? Clin. Cancer Res. 28, 2980\u20132982 (2022).","journal-title":"Clin. Cancer Res."},{"key":"67254_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jconrel.2021.11.016","volume":"341","author":"T Zhang","year":"2022","unstructured":"Zhang, T. et al. Nano-engineered immune cells as \u201cguided missiles\u201d for cancer therapy. J. Control. Release 341, 60\u201379 (2022).","journal-title":"J. Control. Release"},{"key":"67254_CR43","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1517\/17425247.2015.966684","volume":"12","author":"MJ Mitchell","year":"2015","unstructured":"Mitchell, M. J. & King, M. R. Leukocytes as carriers for targeted cancer drug delivery. Expert. Opin. Drug Deliv. 12, 375\u2013392 (2015).","journal-title":"Expert. Opin. Drug Deliv."},{"key":"67254_CR44","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park, W., Chawla, A. & O\u2019Reilly, E. M. Pancreatic cancer: a review. JAMA 326, 851\u2013862 (2021).","journal-title":"JAMA"},{"key":"67254_CR45","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","volume":"20","author":"C Springfeld","year":"2023","unstructured":"Springfeld, C. et al. Neoadjuvant therapy for pancreatic cancer. Nat. Rev. Clin. Oncol. 20, 318\u2013337 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"67254_CR46","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00262-011-1182-4","volume":"61","author":"GJ Ullenhag","year":"2012","unstructured":"Ullenhag, G. J. et al. Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy. Cancer Immunol. Immunother. 61, 725\u2013732 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"67254_CR47","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","volume":"45","author":"A Schietinger","year":"2016","unstructured":"Schietinger, A. et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45, 389\u2013401 (2016).","journal-title":"Immunity"},{"key":"67254_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59529-0","volume":"16","author":"R Trehan","year":"2025","unstructured":"Trehan, R. et al. SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases. Nat. Commun. 16, 4242 (2025).","journal-title":"Nat. Commun."},{"key":"67254_CR49","doi-asserted-by":"publisher","first-page":"116052","DOI":"10.1016\/j.biopha.2023.116052","volume":"170","author":"Y Takeuchi","year":"2024","unstructured":"Takeuchi, Y. et al. Exhaustion, rather than lack of infiltration and persistence, of CAR-T cells hampers the efficacy of CAR-T therapy in an orthotopic PDAC xenograft model. Biomed. Pharmacother. 170, 116052 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"67254_CR50","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/cas.15261","volume":"113","author":"H Tian","year":"2022","unstructured":"Tian, H. et al. Complement C1q binding protein regulates T cells\u2019 mitochondrial fitness to affect their survival, proliferation, and anti-tumor immune function. Cancer Sci. 113, 875\u2013890 (2022).","journal-title":"Cancer Sci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67254-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67254-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67254-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:02:59Z","timestamp":1768528979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67254-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67254"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67254-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"562"}}